Efficacy and Safety of Albumin in Critically Ill Adults: A Systematic Review
Emergency Medicine International · 2026-01 · 2026 (1)
DOI: 10.1155/emmi/7434218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Emergency Medicine International, online erschienen am 20.07.2026. Verfasst von Talía Gabriela Porras Suárez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Public University of Navarra, Pamplona, Navarra, Spain, unavarra.es. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Albumin, the most abundant blood protein, is widely used as a plasma expander in critically ill patients.
Objective
To evaluate the efficacy and safety of albumin compared to other alternatives in the prevention and treatment of complications in critically ill adults, considering different comparators and clinical situations.
Methods
A systematic review was conducted, including randomized controlled trials (RCTs) comparing albumin with crystalloids, other colloids, or standard care without albumin. Primary outcomes were total mortality, blood transfusion requirement, and serious adverse events. The search was performed in MEDLINE, Embase, and Cochrane Central. Meta‐analysis was conducted using the Mantel–Haenszel method with a random‐effects model, and heterogeneity was assessed with the I 2 statistic. The risk of bias was evaluated using Cochrane RevMan 5.4, and the quality of evidence was assessed with the GRADE approach.
Results
Thirty‐five RCTs involving 13,975 critically ill adults were included. Mortality was 23.8% (1327/5586) with albumin and 24.2% (1361/5618). Compared with colloids, mortality was 21.9% (83/379) versus 24.4% (113/463). When compared with standard care without albumin, mortality was higher with albumin: 15.8% (60/380) versus 9.2% (39/424). SAEs occurred in 37.6% (298/793) of albumin‐treated patients versus 33.5% (266/793) with crystalloids. Albumin required less transfused blood volume than colloids.
Conclusions
Albumin showed no benefit over crystalloids, colloids, or standard care without albumin in reducing mortality. It resulted in less blood transfusions compared to colloids, but serious adverse events were higher than with crystalloids.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, Public University of Navarra, Pamplona, Navarra, Spain, unavarra.es.
- Innovation and Organization Unit, SNS-O, Pamplona, Navarra, Spain.
- Intensive Medicine Service, University Hospital of Navarra, Pamplona, Navarra, Spain, cun.es.
- Pharmaceutical Benefit Management Service, Pharmacy and Benefits Subdirectorate, SNS-O, Pamplona, Navarra, Spain.
ORCID-Profile: Talía Gabriela Porras Suárez, Marta Gutiérrez Valencia, Luis Carlos Saiz, Juan Pedro Tirapu León, Amaia Egüés Lugea, Leire Leache Alegría, Juan Erviti
Zitieren
APA
Suárez, T. G. P., Valencia, M. G., Saiz, L. C., León, J. P. T., Hernández, A. A., Lugea, A. E., Alegría, L. L., & Erviti, J. (2026). Efficacy and Safety of Albumin in Critically Ill Adults: A Systematic Review. Emergency Medicine International, 2026(1). https://doi.org/10.1155/emmi/7434218
Vancouver
Suárez TGP, Valencia MG, Saiz LC, León JPT, Hernández AA, Lugea AE, et al. Efficacy and Safety of Albumin in Critically Ill Adults: A Systematic Review. Emergency Medicine International. 2026;2026(1). doi:10.1155/emmi/7434218
BibTeX
@article{Surez2026,
author = {Suárez, Talía Gabriela Porras and Valencia, Marta Gutiérrez and Saiz, Luis Carlos and León, Juan Pedro Tirapu and Hernández, Aitor Ansotegui and Lugea, Amaia Egüés and Alegría, Leire Leache and Erviti, Juan},
title = {Efficacy and Safety of Albumin in Critically Ill Adults: A Systematic Review},
journal = {Emergency Medicine International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/emmi/7434218}
}
EUVIMED